INTUITIVE SURGICAL INC
Intuitive Surgical (ISRG) is the dominant name in robotic-assisted surgery, best known for its da Vinci surgical systems that enable minimally invasive procedures. With a sizeable installed base and recurring revenue from instruments, accessories and service contracts, the company has built a high-margin business that benefits as hospitals upgrade systems and expand robotic programmes. Key growth drivers include wider clinical adoption across specialties, new product introductions and expansion into less invasive procedures. Investors should weigh these opportunities against concentration risks — substantial reliance on a single product family, ongoing R&D spending, regulatory and reimbursement dynamics, and sensitivity to hospital capital budgets. Competition from established medical groups and new robotics entrants is rising. The market cap (~$165.9bn) reflects premium expectations of persistent growth and margin expansion; such expectations can reverse. This overview is educational and not investment advice — consider your risk tolerance and seek personalised guidance before acting.
Why It's Moving
Fresh Analyst Upgrades Fuel ISRG's Bullish 2026 Outlook with Over 20% Upside Potential
- Barclays raised its target to $651 on April 23, implying significant upside from robust da Vinci 5 adoption and 19% procedure growth in recent quarters.
- Leerink Partners and Baird followed on April 22 with an average target of $611, citing upcoming catalysts like new platforms in cardiac and endoluminal procedures.
- Consensus across 44 analysts rates ISRG a Strong Buy, driven by recurring revenue strength and positive 2026 earnings revisions up 9.5%.
Fresh Analyst Upgrades Fuel ISRG's Bullish 2026 Outlook with Over 20% Upside Potential
- Barclays raised its target to $651 on April 23, implying significant upside from robust da Vinci 5 adoption and 19% procedure growth in recent quarters.
- Leerink Partners and Baird followed on April 22 with an average target of $611, citing upcoming catalysts like new platforms in cardiac and endoluminal procedures.
- Consensus across 44 analysts rates ISRG a Strong Buy, driven by recurring revenue strength and positive 2026 earnings revisions up 9.5%.
When is the next earnings date for INTUITIVE SURGICAL INC (ISRG)?
Intuitive Surgical (ISRG) is estimated to report its next earnings between July 17 and July 23, 2026, following the recent Q1 2026 release on April 21, 2026. This upcoming report will cover the second quarter of 2026 (Q2), aligning with the company's historical pattern of late-July announcements after market close. No specific date has been officially confirmed yet.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intuitive Surgical's stock with a target price of $611.14, indicating strong growth potential.
Financial Health
Intuitive Surgical is performing well with strong revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring ISRG
Niche Dominators
These carefully selected companies rule their specialized markets by design. They've built powerful competitive advantages in focused segments that larger companies often overlook, creating a path to consistent profits and sustainable growth.
Published: June 17, 2025
Explore BasketPatient Platforms
This carefully curated collection features companies building the technological foundations that will power innovation for decades to come. Our analysts have identified businesses creating essential infrastructure in genomics, AI, robotics, and advanced computing—platforms that could define their industries and generate substantial long-term returns.
Published: June 17, 2025
Explore BasketAI & Robotics Architects
Invest in companies that own the foundational patents powering our AI future. These carefully selected stocks represent firms whose intellectual property forms the blueprint for machine learning and automation, giving them a powerful competitive advantage for years to come.
Published: June 17, 2025
Explore BasketRestless Innovators
Companies that refuse to stand still, constantly pushing boundaries and redefining what's possible. These stocks have been carefully selected by our analysts for their relentless pursuit of innovation and potential for long-term growth.
Published: June 17, 2025
Explore BasketFuture Tech: World Changing Ideas
Get ahead of tomorrow's innovations with this collection of stocks pushing technological boundaries. Our analysts have carefully selected companies developing flying cars, breakthrough medical treatments, and robotic surgery that could reshape our future.
Published: May 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue model
Consumables and service contracts create predictable follow-on sales, though hospital budgets and procedure volumes can affect revenue.
Innovation and R&D
Regular product updates and new platforms can open markets, but they require heavy R&D and face regulatory hurdles.
Global adoption trends
Growing use of minimally invasive surgery offers a large addressable market, yet adoption and reimbursement vary by region.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
